Novavax faces setback as USFDA halts COVID-Flu vaccine trial over nerve damage report
Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor neuropathy.
Written By : Farhat Nasim
Published On 2024-10-17 09:43 GMT | Update On 2024-10-17 09:43 GMT
Bengaluru: The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage, the company said on Wednesday.
Its shares plunged as much as 24%, and if losses hold, it would wipe off nearly $400 million from the vaccine maker's market capitalization.
The stock drop also reflect concerns on whether the hold would impact Novavax's partnership with French drugmaker Sanofi , according to one analyst.
Novavax said a participant enrolled in a mid-stage study of the combination vaccine last month reported symptoms of motor neuropathy, or damage to the nerve cells that control muscles or movement. The person was given the vaccine in January last year.
The company said it was not yet established that the vaccine had caused the safety event and it was working with the FDA to resolve the pause.
"Our goal is to successfully resolve this matter and to start our Phase 3 trial as soon as possible," Chief Medical Officer Robert Walker said.
At least two analysts said it was too early to draw a conclusion. Jefferies analyst Roger Song said motor neuropathy was not a side effect seen in any older trials of Novavax's shots.
Still, the pause fueled investor worries over the company's growth as its COVID-19 shot, Novavax's only approved product, faces low demand after a late entry into the U.S. market.
The company in May had signed a deal worth at least $1.2 billion with Sanofi to co-sell Novavax's vaccine in most countries and use the COVID shot along with its own flu vaccines to develop a combination shot.
Sanofi said the clinical hold has "nothing to do with" its partnership with Novavax. Outside of the agreement, the companies can individually develop their own flu-COVID vaccines and other products, it said in an e-mailed statement.
"Fundamentally this doesn't seem to have a direct impact on Novavax's partnership with Sanofi," TD Cowen analyst Brendan Smith said.
Investors will closely monitor what additional data the FDA asks for, he said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.